ANIP
ANI Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
ANIP fundamentals
ANI Pharmaceuticals (ANIP) Revenue Breakdown: Q3 2025 Business & Regional Performance
ANI Pharmaceuticals (ANIP) reported total revenue of 227.81M USD in Q3 2025, with its core business segment Generic Pharmaceutical Products contributing 43.32%. Regionally, United States remained the largest market, accounting for 99.18% of total revenue. Explore ANI Pharmaceuticals's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
ANI Pharmaceuticals (ANIP) reported total revenue of 227.81M USD in Q3 2025, with its core business segment Generic Pharmaceutical Products contributing 43.32%. Regionally, United States remained the largest market, accounting for 99.18% of total revenue. Explore ANI Pharmaceuticals's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What were the key takeaways from ANI Pharmaceuticals’s earnings call?What factors drove the changes in ANI Pharmaceuticals's revenue and profit?What guidance did ANI Pharmaceuticals's management provide for the next earnings period?Did ANI Pharmaceuticals beat or miss consensus estimates last quarter?What is ANI Pharmaceuticals's gross profit margin?What were the key takeaways from ANI Pharmaceuticals's earnings call?What is the market's earnings forecast for ANI Pharmaceuticals next quarter?What is the revenue and EPS growth rate for ANI Pharmaceuticals year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
